{"nctId":"NCT00709852","briefTitle":"Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging","startDateStruct":{"date":"2008-06"},"conditions":["Diagnostic Imaging","Central Nervous System Diseases"],"count":402,"armGroups":[{"label":"Gadobutrol then Gadoteridol","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug: Gadoteridol (ProHance)"]},{"label":"Gadoteridol then Gadobutrol","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug: Gadoteridol (ProHance)"]}],"interventions":[{"name":"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","otherNames":[]},{"name":"Gadoteridol (ProHance)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is at least 18 years of age\n* Is referred for a contrast-enhanced MRI of the CNS based on current clinical symptoms or results of a previous imaging procedure\n* Has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability Act (HIPAA) as applicable, and has consented to participate\n\nExclusion Criteria:\n\n* Has any contraindication to the MRI examinations or the use of Gd-containing contrast agents\n* Has a history of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents\n* Has severe cardiovascular disease (eg, known long QT syndrome, acute myocardial infarction \\[\\< 14 days\\], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (\\< 48 hours)- Patients with acute renal insufficiency of any severity due to hepato-renal syndrome or in the perioperative liver transplantation period","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 1 (BR1)","description":"BR1 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":"0.14"},{"groupId":"OG001","value":"2.21","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"0.37"},{"groupId":"OG001","value":"2.70","spread":"0.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.16","spread":"0.26"},{"groupId":"OG001","value":"1.78","spread":"0.44"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 2 (BR2)","description":"BR2 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.28"},{"groupId":"OG001","value":"2.60","spread":"0.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.19","spread":"0.49"},{"groupId":"OG001","value":"2.91","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.46","spread":"0.37"},{"groupId":"OG001","value":"2.28","spread":"0.47"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Blinded Reader 3 (BR3)","description":"BR3 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.16"},{"groupId":"OG001","value":"2.02","spread":"0.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"0.32"},{"groupId":"OG001","value":"2.16","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.32"},{"groupId":"OG001","value":"1.76","spread":"0.39"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic Resonance Imaging (MRI) Compared to Unenhanced MRI by Average Reader (AR)","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.15"},{"groupId":"OG001","value":"2.26","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"0.30"},{"groupId":"OG001","value":"2.58","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.24"},{"groupId":"OG001","value":"1.93","spread":"0.36"}]}]}]},{"type":"PRIMARY","title":"Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Readers","description":"The blinded readers evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another to determine the total number of lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.41","spread":"13.05"},{"groupId":"OG001","value":"7.80","spread":"12.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.07","spread":"16.60"},{"groupId":"OG001","value":"9.63","spread":"15.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.75","spread":"8.97"},{"groupId":"OG001","value":"7.31","spread":"9.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.08","spread":"12.39"},{"groupId":"OG001","value":"8.25","spread":"11.40"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)","description":"BR1 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.04"},{"groupId":"OG001","value":"2.62","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":"0.21"},{"groupId":"OG001","value":"2.95","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.22"},{"groupId":"OG001","value":"2.03","spread":"0.33"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)","description":"BR2 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.45"},{"groupId":"OG001","value":"3.28","spread":"0.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":"0.33"},{"groupId":"OG001","value":"3.22","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"0.31"},{"groupId":"OG001","value":"2.54","spread":"0.27"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)","description":"BR3 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"0.14"},{"groupId":"OG001","value":"2.39","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"0.20"},{"groupId":"OG001","value":"2.25","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"0.21"},{"groupId":"OG001","value":"1.85","spread":"0.26"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"0.16"},{"groupId":"OG001","value":"2.76","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"0.17"},{"groupId":"OG001","value":"2.81","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"0.16"},{"groupId":"OG001","value":"2.14","spread":"0.18"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 1 (BR1)","description":"BR1 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.30"},{"groupId":"OG001","value":"1.69","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"0.74"},{"groupId":"OG001","value":"2.40","spread":"0.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"0.47"},{"groupId":"OG001","value":"1.48","spread":"0.74"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 2 (BR2)","description":"BR2 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":"0.31"},{"groupId":"OG001","value":"1.75","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":"0.83"},{"groupId":"OG001","value":"2.51","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.47","spread":"0.67"},{"groupId":"OG001","value":"1.95","spread":"0.83"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Blinded Reader 3 (BR3)","description":"BR3 evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"0.30"},{"groupId":"OG001","value":"1.55","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.72","spread":"0.63"},{"groupId":"OG001","value":"2.05","spread":"0.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"0.60"},{"groupId":"OG001","value":"1.64","spread":"0.70"}]}]}]},{"type":"PRIMARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader (AR)","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.26"},{"groupId":"OG001","value":"1.62","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"0.62"},{"groupId":"OG001","value":"2.26","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"0.47"},{"groupId":"OG001","value":"1.65","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Average Reader","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"0.14"},{"groupId":"OG001","value":"2.22","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":"0.28"},{"groupId":"OG001","value":"2.55","spread":"0.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.22"},{"groupId":"OG001","value":"1.90","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Number of Lesions for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Average Reader","description":"The AR analysis used the mean of the values for the 3 blinded readers","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.08","spread":"12.39"},{"groupId":"OG001","value":"8.24","spread":"11.79"}]}]}]},{"type":"SECONDARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader","description":"The AR analysis used the mean of the values for the 3 blinded readers.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"0.51"},{"groupId":"OG001","value":"2.24","spread":"0.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"0.39"},{"groupId":"OG001","value":"2.56","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.94","spread":"0.34"},{"groupId":"OG001","value":"1.91","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader","description":"The AR analysis used the mean of the values for the 3 blinded readers","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.25","spread":"11.40"},{"groupId":"OG001","value":"8.24","spread":"11.79"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With More Lesions Detected for Combined Unenhanced/Gadobutrol-enhanced MRI or for Unenhanced MRI by Blinded Readers","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another and determined the number of lesion from each.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"34.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4","spread":null},{"groupId":"OG001","value":"40.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"44.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With More Lesions Detected for Combined Unenhanced/Gadoteridol-enhanced MRI or for Unenhanced MRI by Average Reader","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the unenhanced MRI in one session and the images from the combined unenhanced and gadoteridol-enhanced MRIs in another and determined the number of lesion from each.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With More Lesions Detected for Combined Unenhanced/Gadobutrol-enhanced MRI or for Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader","description":"The AR analysis used the mean of the values for the 3 blinded readers. The 3 BRs evaluated the images from the combined unenhanced and gadobutrol-enhanced MRIs in one session and the images from the combined unenhanced and gadoteridol-enhanced MRIs in another and determined the number of lesion from each.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadobutrol-enhanced MRIs. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.16","spread":"0.62"},{"groupId":"OG001","value":"2.90","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"0.55"},{"groupId":"OG001","value":"2.38","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadobutrol-enhanced MRIs in another to determine the total number of lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":"7.99"},{"groupId":"OG001","value":"3.75","spread":"8.09"}]}]}]},{"type":"SECONDARY","title":"Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadobutrol-enhanced MRIs. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.55"},{"groupId":"OG001","value":"2.90","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.48"},{"groupId":"OG001","value":"2.40","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadobutrol-enhanced MRIs. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.20","spread":"0.95"},{"groupId":"OG001","value":"2.94","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":"0.80"},{"groupId":"OG001","value":"2.36","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadoteridol-enhanced MRIs. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"0.61"},{"groupId":"OG001","value":"2.88","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.78","spread":"0.55"},{"groupId":"OG001","value":"2.36","spread":"0.49"}]}]}]},{"type":"SECONDARY","title":"Number of Lesions for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadoteridol-enhanced MRIs in another to determine the total number of lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":"7.99"},{"groupId":"OG001","value":"3.74","spread":"8.15"}]}]}]},{"type":"SECONDARY","title":"Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Normal Structures for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadoteridol-enhanced MRIs. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.13","spread":"0.55"},{"groupId":"OG001","value":"2.91","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.48"},{"groupId":"OG001","value":"2.39","spread":"0.43"}]}]}]},{"type":"SECONDARY","title":"Scores for Two Visualization Parameters (Border Delineation and Internal Morphology) for Lesions for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the unenhanced MRI and the images from the combined unenhanced and gadoteridol-enhanced MRIs. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"0.94"},{"groupId":"OG001","value":"2.88","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.83","spread":"0.79"},{"groupId":"OG001","value":"2.34","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the combined unenhanced and gadobutrol-enhanced MRIs and the images from the combined unenhanced and gadoteridol-enhanced MRIs. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.67","spread":"0.70"},{"groupId":"OG001","value":"2.60","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.95","spread":"0.55"},{"groupId":"OG001","value":"2.91","spread":"0.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"0.45"},{"groupId":"OG001","value":"2.39","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Number of Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the combined unenhanced and gadobutrol-enhanced MRIs and the combined unenhanced and gadoteridol-enhanced MRIs in another to determine the total number of lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"8.09"},{"groupId":"OG001","value":"3.74","spread":"8.15"}]}]}]},{"type":"SECONDARY","title":"Scores for Contrast Enhancement, Border Delineation and Internal Morphology for Normal Structures for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the combined unenhanced and gadobutrol-enhanced MRIs and the images from the combined unenhanced and gadoteridol-enhanced MRIs. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.88","spread":"0.52"},{"groupId":"OG001","value":"2.85","spread":"0.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":"0.54"},{"groupId":"OG001","value":"2.91","spread":"0.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":"0.44"},{"groupId":"OG001","value":"2.39","spread":"0.43"}]}]}]},{"type":"SECONDARY","title":"Scores for Contrast Enhancement, Border Delineation and Internal Morphology for Lesions for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The clinical investigators evaluated the images from the combined unenhanced and gadobutrol-enhanced MRIs and the images from the combined unenhanced and gadoteridol-enhanced MRIs. Contrast enhancement was scored on a 4-point scale where 1 = no enhancement and 4 = excellent enhancement. Border delineation was scored on a 4-point scale where 1 = no or unclear delineation and 4 = excellent delineation. Internal morphology was scored on a 3-point scale where 1 = poorly visible and 3 = sufficiently visible.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":"1.21"},{"groupId":"OG001","value":"2.34","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.04","spread":"0.88"},{"groupId":"OG001","value":"2.94","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":"0.63"},{"groupId":"OG001","value":"2.39","spread":"0.69"}]}]}]},{"type":"SECONDARY","title":"Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the BRs. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. The accuracy of the majority reader diagnoses for the combined unenhanced/gadobutrol-enhanced and the unenhanced MR images were evaluated for consistency with the final clinical diagnosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null},{"groupId":"OG001","value":"64.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. The accuracy of the investigator diagnoses for the combined unenhanced/gadobutrol-enhanced and the unenhanced MR images were evaluated for consistency with the final clinical diagnosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the BRs. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. The accuracy of the majority reader diagnoses for the combined unenhanced/gadoteridol-enhanced and the unenhanced MR images were evaluated for consistency with the final clinical diagnosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.9","spread":null},{"groupId":"OG001","value":"65.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. The accuracy of the investigator diagnoses for the combined unenhanced/gadoteridol-enhanced and the unenhanced MR images were evaluated for consistency with the final clinical diagnosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.2","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the BRs. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. The accuracy of the majority reader diagnoses for the combined unenhanced/gadobutrol-enhanced and the combined unenhanced/gadoteridol-enhanced MR images were evaluated for consistency with the final clinical diagnosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage (Per.) of the Exact Diagnostic Matches (Accuracy of Diagnosis) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. The accuracy of the clinical investigator diagnoses for the combined unenhanced/gadobutrol-enhanced and the combined unenhanced/gadoteridol-enhanced MR images were evaluated for consistency with the final clinical diagnosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"78.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) matches the standard of truth for the presence or absence of abnormal brain tissue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) correctly detects abnormal brain tissue as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"76.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) correctly excludes abnormal brain tissue as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"80.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) matches the standard of truth for the presence or absence of abnormal brain tissue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) correctly detects abnormal brain tissue as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.6","spread":null},{"groupId":"OG001","value":"75.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) correctly excludes abnormal brain tissue as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) matches the standard of truth for the presence or absence of abnormal brain tissue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"77.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) correctly detects abnormal brain tissue as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"75.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Normal/Abnormal Brain Tissue for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader Using T1-weighted (T1w) Images","description":"The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs for the T1w assessment (normal or abnormal). The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) correctly excludes abnormal brain tissue as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.3","spread":null},{"groupId":"OG001","value":"82.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) matches the standard of truth for the presence or absence of malignant lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"87.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) correctly detects malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null},{"groupId":"OG001","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) correctly excludes malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) matches the standard of truth for the presence or absence of malignant lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"95.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) correctly detects malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"88.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (unenhanced or Gadobutrol-enhanced) correctly excludes malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"98.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) matches the standard of truth for the presence or absence of malignant lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"85.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) correctly detects malignant lesions as defined by the independent truth committee","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null},{"groupId":"OG001","value":"60.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) correctly excludes malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) matches the standard of truth for the presence or absence of malignant lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null},{"groupId":"OG001","value":"94.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) correctly detects malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"87.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (unenhanced or Gadoteridol-enhanced) correctly excludes malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) matches the standard of truth for the presence or absence of malignant lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.7","spread":null},{"groupId":"OG001","value":"85.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) correctly detects malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"60.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Majority Reader","description":"The presence of malignant lesions was derived from the diagnoses given on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The majority reader diagnosis was the diagnosis provided by at least 2 of the 3 BRs. The final clinical diagnosis was provided by an independent truth committee not using the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) correctly excludes malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"97.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Accuracy = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) matches the standard of truth for the presence or absence of malignant lesions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null},{"groupId":"OG001","value":"94.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Sensitivity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Sensitivity = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) correctly detects malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"87.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Specificity of Detection of Malignant Lesions (ML) for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The presence of malignant lesions was derived from the diagnoses given by the investigator on the evaluation of the unenhanced image set and the combined unenhanced/enhanced image sets. The final clinical diagnosis was provided by an independent truth committee following evaluation of findings from referral through a 3-month follow-up period, not including the study-specific MR image sets. Specificity = percentage of participants for which the imaging modality (Gadobutrol-enhanced or Gadoteridol-enhanced) correctly excludes malignant lesions as defined by the independent truth committee.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Average Reader","description":"The BRs recorded his/her confidence in diagnosis for the unenhanced MR image set and the combined unenhanced/enhanced MR image sets. The degree of confidence was rated on a 4-point scale where 1 = not confident and 4 = very confident. The AR score was the mean of the means of the 3 BRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"0.48"},{"groupId":"OG001","value":"2.80","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Average Reader","description":"The BRs recorded his/her confidence in diagnosis for the unenhanced MR image set and the combined unenhanced/enhanced MR image sets. The degree of confidence was rated on a 4-point scale where 1 = not confident and 4 = very confident. The AR score was the mean of the means of the 3 BRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"0.48"},{"groupId":"OG001","value":"2.80","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Average Reader","description":"The BRs recorded his/her confidence in diagnosis for the combined unenhanced/enhanced MR image sets. The degree of confidence was rated on a 4-point scale where 1 = not confident and 4 = very confident. The AR score was the mean of the means of the 3 BRs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.80","spread":"0.54"},{"groupId":"OG001","value":"2.80","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The investigator recorded his/her confidence in diagnosis for the unenhanced MR image set and the combined unenhanced/gadobutrol-enhanced MR image sets. The degree of confidence was rated on a 4-point scale where 1 = not confident and 4 = very confident.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"1.02"},{"groupId":"OG001","value":"3.35","spread":"0.76"}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence for Combined Unenhanced/Gadoteridol-enhanced MRI Compared to Unenhanced MRI by Clinical Investigator","description":"The investigator recorded his/her confidence in diagnosis for the unenhanced MR image set and the combined unenhanced/gadoteridol-enhanced MR image sets. The degree of confidence was rated on a 4-point scale where 1 = not confident and 4 = very confident.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.59","spread":"1.02"},{"groupId":"OG001","value":"3.31","spread":"0.79"}]}]}]},{"type":"SECONDARY","title":"Diagnostic Confidence for Combined Unenhanced/Gadobutrol-enhanced MRI Compared to Combined Unenhanced/Gadoteridol-enhanced MRI by Clinical Investigator","description":"The investigator recorded his/her confidence in diagnosis for the combined unenhanced/gadobutrol-enhanced MR image sets and the combined unenhanced/gadoteridol MR image sets. The degree of confidence was rated on a 4-point scale where 1 = not confident and 4 = very confident.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":"0.76"},{"groupId":"OG001","value":"3.31","spread":"0.79"}]}]}]},{"type":"SECONDARY","title":"Comparison of Image Quality Between Gadobutrol and Gadoteridol by Blinded Readers","description":"The BRs evaluated the relative image quality of the gadobutrol-enhanced T1w MR images and the gadoteridol-enhanced T1w MR images in a paired fashion on a 5-point scale where 1 = image on right was worse, 2 = image on right was slightly worse, 3 = both images were the same, 4 = image on right was slightly better, and 5 = image on right was better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"1.24"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants for Which Blinded Readers Said Image Quality Was Higher","description":"Percentage of participants for which blinded readers said image quality was higher","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.0","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"24.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of the Number of Contrast-enhanced Lesions for Gadobutrol and Gadoteridol by Blinded Readers","description":"Two BRs independently provided the number of contrast-enhanced lesions for gadobutrol and gadoteridol. In cases of disagreement between the readers, an independent adjudicator provided the number of contrast-enhanced lesions. The adjudicator results were used in the analysis in the cases of disagreement between the original readers","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"4.74"},{"groupId":"OG001","value":"1.73","spread":"4.89"}]}]}]},{"type":"SECONDARY","title":"Percentage of Lesion Enhancement From Unenhanced to Combined Unenhanced/Enhanced for Gadobutrol and Gadoteridol by Blinded Readers","description":"From the quantitative signal intensity values assessed by the BR, the percentage of lesion enhancement from unenhanced to combined unenhanced/enhanced was calculated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.1","spread":"58.4"},{"groupId":"OG001","value":"77.7","spread":"52.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":399},"commonTop":["Nausea","Headache","Diarrhoea","Dizziness","Dysgeusia"]}}}